The present disclosure relates to a variant polypeptide having attenuated dihydrodipicolinate reductase activity and a method of producing L-threonine using the same.

The present disclosure relates to a modified polypeptide, in which the activity of meso-diaminopimelate is weakened, and a method for producing L-threonine using the same.

Provided are Corynebacterium glutamicum that produces L-lysine, a method for constructing the L-lysine producing strain, and a method for producing L-lysine from the strain. The lysine yield and glucose conversion of the L-lysine producing strain are improved, thereby reducing the production cost.

The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.

Disclosed is an NADH-dependent amino acid dehydrogenase and an application thereof in increasing lysine yield. The amino acid dehydrogenases are aspartate dehydrogenase derived from Pseudomonas aeruginos, aspartate semialdehyde dehydrogenase derived from Tistrella mobilis, dihydropyridine dicarboxylic acid reductase derived from Mycobacterium tuberculosis, and diaminopimelate dehydrogenase derived from Tepidanaerobacter acetatoxydans. The amino acid sequences thereof are as shown in SEQ ID NOs: 1, 3, 5, and 7, respectively. NADH or both NADH and NADPH can be used as co-factors of the amino acid dehydrogenase to synthesize lysine, thereby reducing the demand for NADPH in the cell, and significantly increasing the production of lysine or pentanediamine.

Provided are a polynucleotide having promoter activity and an application of the polynucleotide in producing an amino acid. Also disclosed are a transcription expression cassette, a recombinant expression vector, and a recombinant host cell which contain the polynucleotide, and a method for enhancing expression of a target gene, a method for preparing a protein, and a method for producing an amino acid. The polynucleotide having the promoter activity is a mutant of a polynucleotide having the sequence as shown in SEQ ID NO: 9. Compared with the polynucleotide having the sequence as shown in SEQ ID NO: 9, the promoter activity of the mutant is significantly enhanced, thereby promoting the stable and efficient expression of the target gene.

The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.

The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.

The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.

Certain C. glutamicum strains overexpress genes coding for enzymes having the function of aspartate-semialdehyde dehydrogenase, aspartate aminotransferase, dihydrodipicolinate synthase, dihydrodipicolinate reductase, diaminopimelate decarboxylase, aspartatokinase and diaminopimelate dehydrogenase. The C. glutamicum strains also express NAD(P)(+) transhydrogenase subunit alpha PntA and NAD(P)(+) transhydrogenase subunit beta PntB of Corynebacterium urealyticum. A method is developed for the fermentative production of L-lysine using such C. glutamicum strains.